journal article·2023-02-09Open access

Neutrophil-inspired photothermo-responsive drug delivery system for targeted treatment of bacterial infection and endotoxins neutralization

Chengnan Li, Yingying Gan, Zongshao Li, Mengjing Fu, Yuzhen Li, Xinran Peng, Yongqiang Yang, Guo-bao Tian, Yi Yan Yang, Peiyan Yuan, Xin Ding

Biomaterials Research· Volume 27· Issue 1

Abstract

Abstract Background P. aeruginosa , a highly virulent Gram-negative bacterium, can cause severe nosocomial infections, and it has developed resistance against most antibiotics. New therapeutic strategies are urgently needed to treat such bacterial infection and reduce its toxicity caused by endotoxin (lipopolysaccharide, LPS). Neutrophils have been proven to be able to target inflammation site and neutrophil membrane receptors such as Toll-like receptor-4 (TLR4) and CD14, and exhibit specific affinity to LPS. However, antibacterial delivery system based on the unique properties of neutrophils has not been reported. Methods A neutrophil-inspired antibacterial delivery system for targeted photothermal treatment, stimuli-responsive antibiotic release and endotoxin neutralization is reported in this study. Specifically, the photothermal reagent indocyanine green (ICG) and antibiotic rifampicin (RIF) are co-loaded into poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NP-ICG/RIF), followed by coating with neutrophil membrane to obtain antibacterial delivery system (NM-NP-ICG/RIF). The inflammation targeting properties, synergistic antibacterial activity of photothermal therapy and antibiotic treatment, and endotoxin neutralization have been studied in vitro. A P. aeruginosa -induced murine skin abscess infection model has been used to evaluate the therapeutic efficacy of the NM-NP-ICG/RIF. Results Once irradiated by near-infrared lasers, the heat generated by NP-ICG/RIF triggers the release of RIF and ICG, resulting in a synergistic chemo-photothermal antibacterial effect against P. aeruginosa (~ 99.99% killing efficiency in 5 min). After coating with neutrophil-like cell membrane vesicles (NMVs), the nanoparticles (NM-NP-ICG/RIF) specifically bind to inflammatory vascular endothelial cells in infectious site, endowing the nanoparticles with an infection microenvironment targeting function to enhance retention time. Importantly, it is discovered for the first time that NMVs-coated nanoparticles are able to neutralize endotoxins. The P. aeruginosa murine skin abscess infection model further demonstrates the in vivo therapeutic efficacy of NM-NP-ICG/RIF. Conclusion The neutrophil-inspired antibacterial delivery system (NM-NP-ICG/RIF) is capable of targeting infection microenvironment, neutralizing endotoxin, and eradicating bacteria through a synergistic effect of photothermal therapy and antibiotic treatment. This drug delivery system made from FDA-approved compounds provides a promising approach to fighting against hard-to-treat bacterial infections.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Photodynamic Therapy Research Studies · Nanoplatforms for cancer theranostics · Photoacoustic and Ultrasonic Imaging

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Pharmaceutical Science (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen 518107, PR China.

Center for Pathogen Research, West China Hospital, Sichuan University, Chengdu 610041, China.

Department of Immunology, School of Medicine, Sun Yat-sen University, Shenzhen 518107, China.

Bioprocessing Technology Institute (BTI), Agency for Science, Technology and Research (A*STAR), 20 Biopolis Way, Centros #06-01, Singapore 138668, Republic of Singapore.

Funding

National Natural Science Foundation of China · Natural Science Foundation of Guangdong Province · Science, Technology and Innovation Commission of Shenzhen Municipality

References (56)

Show source-provided references
1. 10.1002/adma.20180602410.1002/adma.201806024 ↗
2. 10.1016/j.ijmm.2015.11.00410.1016/j.ijmm.2015.11.004 ↗
3. 10.1038/s41579-020-00477-510.1038/s41579-020-00477-5 ↗
4. 10.1038/s41564-019-0581-810.1038/s41564-019-0581-8 ↗
5. 10.1097/QCO.000000000000067710.1097/QCO.0000000000000677 ↗
6. 10.1016/S1473-3099(18)30554-110.1016/S1473-3099(18)30554-1 ↗
7. 10.1038/s41467-019-09463-910.1038/s41467-019-09463-9 ↗
8. 10.1002/advs.20180233310.1002/advs.201802333 ↗
9. 10.3389/fmicb.2019.0091310.3389/fmicb.2019.00913 ↗
10. 10.1016/j.addr.2021.02.01410.1016/j.addr.2021.02.014 ↗
11. Jang JC Li J Gambini L Batugedara HM Sati S Lazar MA Fan L Pellecchia M Nair MG. Human resistin protects against endotoxic shock by blocking LPS-TLR4 interaction Proc. Natl. Acad. Sci. U. S. A. 114(48) (2017) E10399-E10408.10.1073/pnas.1716015114 ↗
12. 10.1016/j.cell.2016.04.01510.1016/j.cell.2016.04.015 ↗
13. 10.1038/nature1368310.1038/nature13683 ↗
14. 10.1016/j.carbpol.2019.11522810.1016/j.carbpol.2019.115228 ↗
15. 10.1039/D0BM00821D10.1039/D0BM00821D ↗
16. 10.1016/j.jcis.2020.05.06710.1016/j.jcis.2020.05.067 ↗
17. 10.1002/adfm.20200355910.1002/adfm.202003559 ↗
18. 10.1016/j.bioactmat.2022.03.02210.1016/j.bioactmat.2022.03.022 ↗
19. 10.1002/adma.20200763010.1002/adma.202007630 ↗
20. 10.1016/j.addr.2021.11390510.1016/j.addr.2021.113905 ↗
21. 10.1002/adfm.20211006310.1002/adfm.202110063 ↗
22. 10.1002/advs.20200278710.1002/advs.202002787 ↗
23. Chu D, Dong X, Shi X, Zhang C, Wang Z. Neutrophil-Based Drug Delivery Systems Adv Mater. 2018;30(22):e1706245.
24. 10.3389/fimmu.2017.0008110.3389/fimmu.2017.00081 ↗
25. 10.1038/nri339910.1038/nri3399 ↗
26. 10.1016/j.biomaterials.2017.05.00310.1016/j.biomaterials.2017.05.003 ↗
27. 10.1016/j.bioactmat.2021.08.00810.1016/j.bioactmat.2021.08.008 ↗
28. 10.1038/s41565-018-0254-410.1038/s41565-018-0254-4 ↗
29. 10.1016/j.bioactmat.2022.02.01710.1016/j.bioactmat.2022.02.017 ↗
30. 10.1021/acsnano.0c0797310.1021/acsnano.0c07973 ↗
31. 10.1007/s12195-018-0555-610.1007/s12195-018-0555-6 ↗
32. 10.1038/s41573-019-0054-z10.1038/s41573-019-0054-z ↗
33. 10.1038/s41467-020-17402-210.1038/s41467-020-17402-2 ↗
34. 10.3389/fimmu.2018.0115410.3389/fimmu.2018.01154 ↗
35. Ramirez D, Berry L, Domalaon R, Brizuela M, Schweizer F. Dilipid Ultrashort Tetrabasic Peptidomimetics Potentiate Novobiocin and Rifampicin Against Multidrug-Resistant Gram-Negative Bacteria, ACS infect. Dis. 2020;6(6):1413–26. 1:CAS:528:DC%2BB3cXosVSjsLY%3D
36. 10.1002/adfm.20210344210.1002/adfm.202103442 ↗
37. 10.1002/advs.20200137410.1002/advs.202001374 ↗
38. 10.1016/j.jconrel.2014.12.01110.1016/j.jconrel.2014.12.011 ↗
39. 10.1021/nl500618u10.1021/nl500618u ↗
40. 10.1186/s12879-020-4811-810.1186/s12879-020-4811-8 ↗
41. 10.1021/acsnano.6b0647710.1021/acsnano.6b06477 ↗
42. 10.1002/adfm.20190567110.1002/adfm.201905671 ↗
43. 10.1016/j.coi.2016.10.00510.1016/j.coi.2016.10.005 ↗
44. 10.1093/infdis/jiq11810.1093/infdis/jiq118 ↗
45. 10.1038/ncomms1265810.1038/ncomms12658 ↗
46. 10.1038/nm.251410.1038/nm.2514 ↗
47. 10.1182/blood.202000494810.1182/blood.2020004948 ↗
48. 10.1016/j.biomaterials.2017.02.02310.1016/j.biomaterials.2017.02.023 ↗
49. 10.1016/j.bioactmat.2021.06.00310.1016/j.bioactmat.2021.06.003 ↗
50. 10.1093/infdis/jiaa77810.1093/infdis/jiaa778 ↗
51. 10.1007/s12274-021-3712-510.1007/s12274-021-3712-5 ↗
52. 10.1186/s40824-021-00246-210.1186/s40824-021-00246-2 ↗
53. 10.1186/s40824-022-00326-x10.1186/s40824-022-00326-x ↗
54. 10.1016/j.actbio.2021.01.02010.1016/j.actbio.2021.01.020 ↗
55. 10.1021/acsinfecdis.2c0019310.1021/acsinfecdis.2c00193 ↗
56. Thamphiwatana S Angsantikul P Escajadillo T Zhang Q Olso J Luk BT Zhang S Fang RH Gao W Nizet V Zhang L. Macrophage-like nanoparticles concurrently absorbing endotoxins and proinflammatory cytokines for sepsis management. Proc. Natl. Acad. Sci. U S A. 14(43) (2017) 11488–11493.10.1073/pnas.1714267114 ↗